Arlene O. Siefker-Radtke, Colin P. Dinney, Yu Shen, Dallas L. Williams, Ashish M. Kamat, H. Barton Grossman and Randall E. Millikan A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer Cancer 119
Article first published online: 22 AUG 2012 | DOI: 10.1002/cncr.27751
Neoadjuvant chemotherapy improves the survival of patients with high-risk urothelial cancer. Sequential chemotherapy is quite active and at least maintains the historic expectation of achieving a cure. The current results strongly reinforce previous experience and suggest that pathologic downstaging to pathologic T1 disease or lower is a useful surrogate for an eventual cure.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.